In this episode, I cover the recent issue with Marathon's pricing of a steriod drug for DMD, updates to Amgen v Sanofi and the new biosimilar lawsuit between Genentech v Amgen as well as the recent patent lawsuit around CRISPR technology between UC Berkeley and the Broad Institute.  We close the episode around the introduction of the new book, Human Genome Editing, and how authorities have provided green lights in different countries to alter baby-genes for therapeutic purposes.